Tara Iyengar

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

Glen J. Weiss, Ross C. Donehower, Tara Iyengar et al. · Investigational New Drugs · 2012 · 56 citations · Full text

Kinase Inhibitor, Medicine, Pharmacology +9

The Clinical Course of Deep Vein Thrombosis in Patients with Gynecologic Cancer

Mark A. Morgan, Tara Iyengar, Beata E Napiorkowski et al. · Gynecologic Oncology · 2002 · 52 citations

Clinical Course, Pulmonary Embolism, Thrombosis +7

A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma

Daniel H. Sterman, Katherine L. Molnar-Kimber, Tara Iyengar et al. · Cancer Gene Therapy · 2000 · 46 citations

Neuro-oncology, Malignant Pleural Mesothelioma, Pleural Disease +3

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.

Raoul Tibes, G. S. Falchook, Daniel D. Von Hoff et al. · Journal of Clinical Oncology · 2010 · 42 citations

Immunology, Available Inhibitor, Pharmacotherapy +22

Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter

Tara Iyengar, Thomas J. Herzog · American Journal of Hospice and Palliative Medicine® · 2002 · 36 citations

Urology, Surgical Oncology, Advanced-stage Ovarian Cancer +13